{"brief_title": "A Comparative Trial of Valacyclovir Hydrochloride ( 256U87 ) and Acyclovir for the Suppression of Anogenital Herpes Infections in HIV-Infected Patients", "brief_summary": "To determine the safety and efficacy of oral valacyclovir hydrochloride ( 256U87 ) compared to acyclovir in the treatment of recurrent anogenital herpes in HIV-infected patients with CD4 counts = or > 100 cells/mm3.", "condition": "HIV Infections", "intervention_type": "Drug", "intervention_name": "Acyclovir", "criteria": "Inclusion Criteria Patients must have: - HIV infection with CD4 counts = or > 100 cells/mm3. - Documented culture of anogenital herpes simplex virus (HSV) within the last 5 years. - History of recurrent anogenital HSV infection, with a recurrence (with or without culture) within 1 year prior to study. Exclusion Criteria Co-existing Condition: Patients with the following symptoms and conditions are excluded: - Malabsorption or vomiting that would potentially limit the retention and absorption of oral therapy. Concurrent Medication: Excluded: - Systemic antiherpes medication. - Interferon. Patients with the following prior conditions are excluded: History of hypersensitivity to acyclovir.", "gender": "All", "minimum_age": "18 Years", "maximum_age": "N/A", "healthy_volunteers": "No", "id": "NCT00002084.xml"}